SOP Transarterielle Chemoembolisation zur Tumortherapie

Die transarterielle Chemoembolisation (TACE) ist ein durchleuchtungsgesteuertes minimalinvasives transarterielles Verfahren zur Behandlung von primären (hepatozelluläres Karzinom, intrahepatisches Cholangiokarzinom) und sekundären Lebertumoren (Lebermetastasen). Sie kombiniert die Wirkung von Chemotherapeutika auf Tumoren bei gleichzeitiger Embolisation von tumorversorgenden arteriellen Gefäßen.

Schlüsselwörter

transarterielle Chemoembolisation - Indikationen - hepatozelluläres Karzinom - intrahepatisches Cholangiokarzinom - Lebermetastasen

Publication History

Article published online:
07 September 2020

• Literatur

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 doi:10.3322/caac.21492
• 2 Cummins ER, Vick KD, Poole GV. Incurable colorectal carcinoma: the role of surgical palliation. Am Surg 2004; 70: 433-437
• 3 Garrean S, Hering J, Saied A. et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008; 195: 508-520 doi:10.1016/j.amjsurg.2007.06.024
• 4 Llovet JM, Fuster J, Bruix J. et al. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120 doi:10.1002/lt.20034
• 5 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol 2015; 33: 550-558 doi:10.1200/JCO.2014.57.9151
• 6 Lim L, Gibbs P, Yip D. et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005; 35: 222-227 doi:10.1111/j.1445-5994.2005.00789.x
• 7 Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-125 doi:10.1053/sonc.2002.31679
• 8 Kerr DJ, Los G. Pharmacokinetic principles of locoregional chemotherapy. Cancer Surv 1993; 17: 105-122
• 9 Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007; 25: 978-986 doi:10.1200/JCO.2006.09.8657
• 10 Konno T, Maeda H, Yokoyama I. et al. [Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma]. Gan To Kagaku Ryoho 1982; 9: 2005-2015
• 11 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 doi:10.1007/s00270-009-9711-7
• 12 Vogl TJ, Zangos S, Eichler K. et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17: 1025-1034 doi:10.1007/s00330-006-0372-5
• 13 Raoul JL, Heresbach D, Bretagne JF. et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70: 585-590
• 14 Sakamoto I, Aso N, Nagaoki K. et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998; 18: 605-619 doi:10.1148/radiographics.18.3.9599386
• 15 Dufour JF, Bargellini I, De Maria N. et al. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013; 24 (Suppl. 02) ii24-ii29 doi:10.1093/annonc/mdt054
• 16 Takayasu K, Arii S, Ikai I. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469 doi:10.1053/j.gastro.2006.05.021
• 17 Lencioni R, de Baere T, Soulen MC. et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016; 64: 106-116 doi:10.1002/hep.28453
• 18 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 doi:10.1053/jhep.2003.50047
• 19 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634 doi:10.1148/radiol.10101058
• 20 Georgiades CS, Hong K, DʼAngelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659 doi:10.1097/01.RVI.0000182185.47500.7A
• 21 Varela M, Real MI, Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481 doi:10.1016/j.jhep.2006.10.020
• 22 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577 doi:10.1016/j.dld.2016.02.005
• 23 Kim JH, Yoon HK, Sung KB. et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113: 1614-1622 doi:10.1002/cncr.23787
• 24 Vogl TJ, Naguib NN, Nour-Eldin NE. et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 2012; 131: 733-740 doi:10.1002/ijc.26407
• 25 Kuhlmann JB, Euringer W, Spangenberg HC. et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012; 24: 437-443 doi:10.1097/MEG.0b013e3283502241
• 26 Ray CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24: 1218-1226 doi:10.1016/j.jvir.2013.03.019
• 27 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
• 28 Stutz M, Mamo A, Valenti D. et al. Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract 2015; 2015: 715102 doi:10.1155/2015/715102
• 29 Kress O, Wagner HJ, Wied M. et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion 2003; 68: 94-101 doi:10.1159/000074522
• 30 Loewe C, Schindl M, Cejna M. et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180: 1379-1384 doi:10.2214/ajr.180.5.1801379
• 31 Pitt SC, Knuth J, Keily JM. et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008; 12: 1951-1960 doi:10.1007/s11605-008-0640-6
• 32 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590-1602 doi:10.1002/cncr.21389
• 33 Eichler K, Jakobi S, Gruber-Rouh T. et al. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82: e816-e822 doi:10.1016/j.ejrad.2013.08.046
• 34 Cho SW, Kitisin K, Buck D. et al. Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010; 2010: 251621 doi:10.1155/2010/251621
• 35 Khoja L, Atenafu EG, Suciu S. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370-1380 doi:10.1093/annonc/mdz176